BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 15204241)

  • 1. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Jun; (7):214-26. PubMed ID: 12230645
    [No Abstract]   [Full Text] [Related]  

  • 5. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Dec; (8):225-35. PubMed ID: 12603879
    [No Abstract]   [Full Text] [Related]  

  • 6. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 7. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present and potential future paradigms for the treatment of ST-segment elevation acute myocardial infarction.
    Chew DP; Moliterno DJ; Herrmann HC
    J Invasive Cardiol; 2002 Feb; 14 Suppl A():3A-20A. PubMed ID: 11847402
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving management of ST-segment elevation myocardial infarction: update on recent data.
    Cannon CP
    Am J Cardiol; 2006 Dec; 98(12A):10Q-21Q. PubMed ID: 17169625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.
    Martinez-Ojeda J; Martinez-Toro J
    Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina].
    Karcz M; Ruzyłło W
    Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recommendations for peri-procedural thrombocyte aggregation inhibition].
    Sauer H; Leschke M
    Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?
    Jackson G
    Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219
    [No Abstract]   [Full Text] [Related]  

  • 18. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal antithrombotic treatment for percutaneous coronary intervention.
    Kadakia RA; Ferguson JJ
    Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.